Corporate Presentation of ranbaxy

8/9/2019 Corporate Presentation of ranbaxy

1/26

Corporate PresentationJan 2010


2/26

Safe Harbor

Except for the historical information contained herein, statements in this presentation and the

subsequent discussions, which include words or phrases such as will, aim, will likely result,

would, believe, may, expect, will continue, anticipate, estimate, intend, plan,

contemplate, seek to, future, objective, goal, likely, project, should, potential, will pursue

" "- .

These forward-looking statements involve a number of risks, uncertainties and other factors that could

cause actual results to differ materially from those suggested by the forward-looking statements. These

risks and uncertainties include, but are not limited to our ability to successfully implement our strategy,

our growth and expansion plans, obtain regulatory approvals, our provisioning policies, technological

c anges, nvestment an us ness ncome, cas ow pro ect ons, our exposure to mar et r s s as we

as other risks. Ranbaxy does not undertake any obligation to update forward-looking statements to

reflect events or circumstances after the date thereof.


3/26

MissionTo become a Research-based International

Pharmaceutical Company

Achieve significant business

with a strong presence in developed markets


4/26

Values

Achieving customer satisfaction is fundamental to our business

Provide products and services of the highest quality

Practice dignity and equity in relationship and provide opportunities for

our people to realise their full potential

Ensure profitable growth and enhance wealth of the shareholders

Foster mutually beneficial relations with all our business partners

Manage our operations with high concern for safety and environment

Be a responsible corporate citizen


5/26

Ranbaxy Overview Indias largest pharmaceutical company

Ranbaxy & Daiichi Sankyo combined rank among the top 20 global

Worldwide Presence

Ground resence in 46 countries roducts sold in over 125 countries

Manufacturing locations in 7 countries

Global consolidated sales US $ 1519 Mn (2009)

Business

- International 77%

- Domestic 23%

>12000 employees globally represented by 50 nationalities


6/26


7/26

The Global Generics AdvantagesGrowth Potential

Patent Expiries ew ar ets

Healthcare Costs

Consolidation

Size & Scale

India Factor

Scientific Talent

Therapeutic Width

Operational Synergies

Cost Advantage Gx / Rx Competencies

Product Portfolio

Move to Specialty/ Niche


8/26

Our Global Presence

North America Latin America

Europe Africa

Asia (incl. Middle East) Japan


9/26

Business ModelGlobal Reach

Developed Markets

Product Portfolio

Generics, , ,

Emerging marketsIndia, Romania, CIS,

South Africa,

Branded & OTC

Brazil, Mexico Competitive Advantages

Aggressive Marketing Low cost of Innovation

ManufacturingResearch &Development

Global Management

Dosage Form API* - Vertical Integration In-house / Outsource

New Chemical Entities Generics / NDDS* Complex / Niche/ FTF*

The India advantage The India advantage

* NDDS - Novel Drug Delivery System, API Active Pharmaceutical Ingredients, FTF First to File


10/26

Global Sales Split

AsiaCIS*

orAmerica

RoW

Europe

API

* CIS includes Russia & Ukraine belt

Global Sales (2009): US $ 1519 Mn


11/26

Evolution of Market Mix

Emerging54%

Others

7%

Developed39%

FY 2005 FY 2009

Improving balance in market mix Growth well spread across geographies

os one o everage var ous mar e oppor un es


12/26

Our Key Geographies

Pioneer entrant from IndiaStrong local presence

North America

Canada: New market, growing rapidly

Well established

EUROPE

Presence in 23 of 27 EU countriesNo. 1 Generic player in RomaniaKey markets - UK, France & Germany

Emerging Markets

Leadership in domestic market- IndiaEstd. Infrastructure in Romania, Brazil, Russia & South AfricaProfitable branded generics markets


13/26

Developed Markets Presence

Largest generic market worldwide

Significant patent expiries through 2011USA

Germany, UK - mature markets

EU

France, Spain, Italy, Romania - emerging markets

Ranbaxy has presence in 23 of the 27 EU countries

Mature generic market

Ranbaxy is the fastest growing generics company in Canada

Emerging generic market, < 5% generic penetration

st

Japan


14/26

Emerging Markets Presence

Leadership position in domestic market

Company growing faster than market

Ranked as the No 1 Generics Company

India

Strategic for servicing EU operationsRomania

Strong base in acute therapies

Fast expanding into chronic and OTC segments

Key market in the African continent

Ukraine

s rong o p ayer n e reg onSouth Africa


15/26

India

Indias largest pharmaceutical company by sales and ranked No 2 by

market share

Company growing faster than market Company has one of the largest distribution networks that comprises

2500+ skilled field force

18 brands in Top 300 of Industry


16/26

Research & Development

State-of-the-art R&D facilitiesbased in India

R&D III

R&D IV


17/26

Research & Development

Dedicated Facilities for Innovative & Generics Research

> 1400 R&D Personnel ~ 300 Doctorates

Highest R&D spender across industry

8 - 10 NCE molecules in i eline

NDDS based products (4 platform technologies)

R&D collaborations

Alliance / Collaboration in

Alliance / Collaboration in

NDDR

Out-licensinOut-licensing

NDDR

In NDDSIn NDDR


18/26

Our Global Manufacturing Strengths

cGMP compliant world-class API & Dosage Forms manufacturing facilities acrossthe globe

7 manufacturing locations worldwide API facilities - increasing vertical integration Creating capacities for specialty products New facilities added in cost advantageous geographies

USAUSA IrelandIreland NigeriaNigeriaRomaniaRomania

IndiaIndia MalaysiaMalaysiaSouth AfricaSouth Africa


19/26

Inorganic Strategy

To capitalize on the opportunities in the ongoing consolidation for

Size and scale in developed & emerging markets

Expansion of geographical reach

Access to niche and complex products / therapeutic areas

Costs efficiencies in manufacturing and R&D

...providing a strategic and value accretive fit


20/26

Acquisitions & Alliances Since 2006

> US $ 500 Mn spend on M&A

Tera ia Romania

Be-Tabs (South Africa)

Orchid (India)

Zenotech (India)

Ethimed (Belgium) Krebs (India)

Derma Brands (USA)

Cardinal Drugs (India)

-


21/26

Ranbaxy Daiichi Sankyo Partnership

A path breaking confluence that redefines the global pharma paradigm

Combines complementary strengths rov es so ut ons to ey nee -gaps or eac organ sat on

Strategic combination creates an Innovator and Generic Pharmaceutical

Powerhouse

Combined entity is ranked among the Top 20 global pharmaceutical

Ranbaxy enters into a new orbit to chart a higher trajectory

Complementary strengths ranging from excellence in NDDR toextensive reach across global markets

Financially & strategically beneficial for all stakeholders


22/26

To become a Global Pharma Innovator

Global Innovator

Achieve scientific and

Pharma

presenceworldwide

technologicalinnovations, create aninnovative business

Pharmaceuticals,develop novel

modeldrugs continuously

Complementary Business Combination

Global Pharma Innovator An Integrated, Research Based,

Company


23/26

Corporate Social Responsibility

An essential component of Ranbaxys CSR is to care for thecommunity

Based on the theme Health For All set up Ranbaxy RuralDevelopment Trust in 1978; later re-christened as RanbaxyCommunity Health Care Society in 1994

Operates in the states of Punjab, Haryana, Himachal

Pradesh, Madhya Pradesh and Delhi/Gurgaon to providen egra e ea care o a ou a peop e s ay ng nvillages and urban slum areas

,promotive services covering areas of maternal child health,family planning, adolescent health, reproductive health andeducation


24/26

Corporate Social Responsibility

AIDS awareness and counselling is a priority component ofthe CSR programme

Established meaningful and useful partnerships with theGovernment, Medical Colleges, NGOs, EducationalInstitutions, Confederation of Indian Industry and other likeminded agencies

Anti-Aids rov es nnovat ve an a or a e ant me c nes Over 5 lakh patients worldwide benefit from Ranbaxys

ARV drugs First in the world Pediatrics ARV

Malaria Research Molecule in Phase III Clinical Trials Intended for patients in developing/ countries


25/26

Corporate Governance

An institutionalized framework of Corporate Governance and Code ofPractices to strengthen decision making and compliance with ethicalinte rit and reliabilit

Board Of Directors

Science Shareholder

Grievance/Transfer

Committees of the Board

Audit Compensation

Management


26/26

Thank You

Corporate Presentation of ranbaxy

Documents

Transcript of Corporate Presentation of ranbaxy